Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2011

View Archived Issues

Novel free fatty acid FFA1 receptor agonists for diabetes claimed by Lilly

Preclinical safety data on FCFD-4514-S enable advancement to clinic for geographic atrophy

Clinical trial tests effect of food, H2R blockade and vitamin C on GSK-1322322 pharmacokinetics

PEM antibiotic POL-7080 well tolerated in phase I study

KAG-308 has beneficial effects in models of chronic colitis

Preclinical data disclosed on RDX-5791 for constipation

New anticancer agents prepared by Chinese scientists

OPKO Health receives grant to support development of therapeutics for Dravet syndrome

Merck & Co. patents novel acyl-CoA desaturase inhibitors

Biodel's ultrarapidly acting insulin formulations enter pump trial in type 1 diabetes

FDA clears Meridian Bioscience's Premier C. difficile GDH immunoassay

Novel antibacterial agents presented

Tibotec designs novel HIV integrase inhibitors

Encore Therapeutics finalizes novel nanoemulsion progesterone formulation ETI-411

New calcitonin CGRP receptor antagonists disclosed

Duquesne University presents new tamoxifen-melatonin hybrid ligand

Nymox to begin recruitment in new clinical trial of NX-1207

Talon Therapeutics to begin recruitment in phase III Marqibo trial

Halozyme and ViroPharma sign agreement to develop subcutaneous Cinryze formulation

Summit nominates SMT-19969 as preclinical development candidate against C. difficile infection

Verona Pharma begins new phase II trial of RPL-554 in asthma

EMA acknowledges that Clinuvel's proposed dossier for afamelanotide meets all filing requirements

Meda completes acquisition of atopic dermatitis treatment Elidel

Hervix has long-term benefit on recurrence of bladder cancer

CrystalGenomics completes phase I trial of CG-400549, an antibiotic against resistant bacteria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...